FIG. 6.

hBD1 and hBD2 inhibit virus infectivity. The R5 isolate BaL (A) and the X4 isolate IIIB (B) were treated with hBD1 and hBD2 at concentrations ranging from 20 to 0.8 μg/ml for 1 h at 37°C. As a control, virus was mock treated with PBS or with 11.2 μg/ml of the fusion inhibitor T20, which is active only in the course of attachment/fusion events but has no direct virus-inactivating properties. Pretreated virus was then centrifuged at 100,000 × g for 1 h, washed, and used to infect target cells. T20 (11.2 μg/ml) was also used at the time of infection (postcentrifugation) as a positive control. Infection was monitored by HIV p24 ELISA for 10 days. Shown here are average results of four independent experiments. Bars indicate standard errors of the means.